AstraZeneca’s CEO, a French-born Australian running an Anglo-Swedish company, is betting $50 billion on a strategy of making the US its largest market — while also pouring $15 billion into China. Each ...

AstraZeneca, in a plot to lower the average age of its workforce, engaged in discrimination when it fired workers who refused COVID-19 vaccines because of religious reasons, a federal lawsuit filed by ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter. It is a diversified fund that focuses on long-term capital appreciation by ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best immunotherapy stocks to buy according to hedge funds. AstraZeneca PLC (NASDAQ:AZN) received an update from Deutsche Bank on February 16, with the firm ...

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...

AstraZeneca has an even larger exposure to oncology, with the segment contributing about 44% of total revenues. Outside of oncology, AstraZeneca has meaningful positions in immuno ...

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

Yet again, AstraZeneca is in a crisis of its own making. The latest in the drug manufacturer’s long string of mishaps and miscommunications came Tuesday, when top federal health officials accused the ...

Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio CAMBRIDGE, England & BOSTON--(BUSINESS ...